This week’s cybersecurity recap covers Firefox and Chrome bugs, EDR-killer tools, a TV botnet, an OpenBSD flaw, Android ...

Most security teams think of NTFS junctions and symbolic links as niche file system features. They let one directory point to another, like a shortcut that the OS treats as real. They exist for ...

The companies at the frontier of artificial intelligence should be ready to slow down, one of the fastest-moving among them says. Anthropic, the maker of the Claude chatbot, has claimed AI systems may ...

Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche ...

This content can't be displayed right now. To view this embed, please accept targeting cookies. It's loaded from a third party and requires that permission to appear. Manage cookie preferences When ...

Random forest regression is a tree-based machine learning technique to predict a single numeric value. A random forest is a collection (ensemble) of simple regression decision trees that are trained ...

With Claude enjoying a moment of newfound popularity among regular people, Anthropic is previewing an update designed to make its chatbot better at explaining some concepts. Starting today, Claude can ...

A new study finds that certain patterns of AI use are driving cognitive fatigue, while others can help reduce burnout. by Julie Bedard, Matthew Kropp, Megan Hsu, Olivia T. Karaman, Jason Hawes and ...

Generate:Biomedicines has earmarked $300 million of its IPO funds to complete a pair of phase 3 asthma trials for its anti-TSLP antibody GB-0895. (Fabrice Cabaud/Stock/Getty Images Plus) ...

Feb 26 (Reuters) - Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares of the U.S.-based drug developer at $16 each. The offering ...

Generate Biomedicines Inc. raised $400 million in an initial public offering, pricing its shares at the midpoint of the marketed range. The Somerville, Massachusetts-based drug developer sold 25 ...